rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Tasly Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Acute Ischemic Stroke

Treatments: Drug: rhPro-UK; Drug: rt-PA

Study type: Interventional

Funder types: Industry

Identifiers

NCT05700591

TASLY-B1440-CTP-Ⅲc

Details and patient eligibility

About

Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this purpose.

RhPro-UK is a specific plasminogen activator. rhPro-UK only acts on occlusive thrombus and has little effect on hemostatic thrombus. In addition, rhPro-UK does not form covalent complexes with protease inhibitors in plasma, so the concentrations of rhpro-UK and protease inhibitors in the blood do not decrease compared with alteplase. Therefore, rhPro-UK therapies have a potential advantage of less systemic bleeding in treated subjects. Data from several previous studies suggest that rhPro-UK is efficacious when used to treat patients with acute myocardial infarction. On April 2, 2011, rhPro-UK injection was approved by the National Medical Products Administration to treat acute myocardial infarction. Since then, rhPro-UK has been widely used to treat myocardial infarction in China.

Since 2016, a phase 2 clinical trial was carried to explore the dosing of rhPro-UK in patients with acute ischemic stroke, followed by another study with a sample size of 680 patients to initially validate the efficacy and safety of the proposed dose of 35mg. The results of these studies suggested that rhPro-UK was effective, and there were no safety concerns. To further prove the efficacy and safety of rhPro-UK in patients with acute ischemic stroke, investigators conducted this phase 3 study (PROST-2).

Enrollment: 1,552 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinically diagnosed as acute ischemic stroke (according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).
2. 18 years or older, male or female.
3. NIH Stroke Scale（NIHSS）scores of 4 to 25.
4. Treatment within 4.5 hours after stroke onset.
5. The symptoms of stroke last at least 30 minutes without significant improvement before treatment.
6. Informed consent by patient or by patient's guardians.

Exclusion criteria

1. Prestroke modified rankin scale of ≥2.
2. Large areas of hypodense ischaemic changes on baseline CT（Infarction area> 1/3 of the middle cerebral artery feeding area）.
3. Intracranial hemorrhage.
4. Previous history of intracranial hemorrhage.
5. Severe cerebral trauma or stroke history within 3 months.
6. Intracranial tumor or giant intracranial aneurysm.
7. Intracranial or intraspinal surgery within the past 3 months.
8. Gastrointestinal or urinary bleeding within the past 3 weeks.
9. History of major surgical procedures or severe trauma within the last 2 weeks (investigator evaluation).
10. Puncture in 1 week which can not be oppressed.
11. Active visceral hemorrhage.
12. Aortic arch dissection.
13. Bacterial endocarditis or pericarditis.
14. Planned for thrombectomy.
15. Patients with systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg after anti-hypertension treatment.
16. High risk of acute hemorrhage include platelet count<10^9/L.
17. Received low molecular weight heparin or heparin within 24 hours.
18. Using of thrombin inhibitors or factor Xa inhibitor within the past 48 hours.
19. Using of oral anticoagulant drugs and PT >15s or INR >1.7.
20. Patients with epilepsy or other mental disorders that could not be adhered to at the beginning of stroke.
21. Blood glucose < 2.8 mmol/L or > 22.2 mmol/L.
22. Allergies to rhPro-UK or rt-PA active ingredients or other components.
23. Pregnant women or beastfeeding women.
24. Participants in other clinical trials within the past month.
25. The investigator believes that the patient is not suitable for the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

1,552 participants in 2 patient groups

rhPro-UK

Experimental group

Description:

Recombinant Human Pro-urokinase (rhPro-UK)

Treatment:

Drug: rhPro-UK

rt-PA

Active Comparator group

Description:

Alteplase(rt-PA)

Treatment:

Drug: rt-PA